April 6, 2020

Orexo ends share buy-back program

Uppsala, Sweden – April 6, 2020. Orexo AB (publ) has ended the program to repurchase its own ordinary shares that was announced on February 17, 2020. A total of 500,000 s...
Read more
April 6, 2020

GenSight Biologics Provides Update on Operations in the Context of COVID-19

Paris, France, April 6, 2020, 7.30 am CET – GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, PEA-PME eligible), a biopharma company focused on discovering an...
Read more
April 3, 2020

BONESUPPORT HOLDING AB (publ) publishes 2019 Annual Report and comments on effects of COVID-19

Lund, Sweden, 15:00 CET, 3 April 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, publishes its annua...
Read more
April 2, 2020

Oncopeptides strengthens its corporate communications function by appointing Rolf Gulliksen as Global Head of Corporate Communications

STOCKHOLM — April 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate communications. Rolf ...
Read more
April 1, 2020

Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021

Oslo, Norway, 1 April 2020 Nordic Nanovector ASA (OSE: NANO) today announces a number of initiatives to speed up recruitment into its pivotal Phase 2b PARADIGME trial wi...
Read more
March 31, 2020

Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection

Gothenburg, March 31, 2020 – Vicore Pharma, a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the submission of a...
Read more
March 30, 2020

Vicore submits clinical trial application for phase II trial with C21 in IPF 2020-03-30

Gothenburg, March 30, 2020 – Vicore Pharma, a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces submission of the c...
Read more
March 27, 2020

Nordic Nanovector ASA publishes 2019 Annual Report

Oslo, Norway, 27 March 2020 On 26 March 2020, the Board of Directors of Nordic Nanovector ASA approved the company’s financial statements for 2019. The company’s 2019 Annual...
Read more
March 26, 2020

Orexo publishes the Annual Report for 2019

Uppsala, Sweden - March 26, 2020 – Orexo’s Annual Report, including the Sustainability Report, for the 2019 fiscal year has been published. The Annual Report can be down...
Read more
March 26, 2020

Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study

STOCKHOLM — March 26, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study evaluating melfluf...
Read more